Drug development is a very risky business. It costs a lot of money and the financial returns are uncertain. The financial returns are even more uncertain if you're dealing with malaria in endemic countries where you're talking about a very low price per treatment as would be sold in the senator's pharmacy. Therefore, they simply cannot undertake this risk by themselves. At the same time, this is where the industrial might and expertise exists. What we really have to do is to take the risk from the pharmaceutical companies, use their expertise, but also make sure that the public interest is maintained. That's what MMV does.
On June 4th, 2015. See this statement in context.